Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGN002 in Refractory Non-Hodgkin Lymphoma
NCT02519270Phase 1Terminated
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- May 2016
- Primary completion
- May 2018
- Modality
- Cytokines & Interferons, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eramkafusp alfa in non-Hodgkin lymphoma (NHL), sponsored by Spectrum Pharmaceuticals, Inc. Primary endpoint: Safety and Tolerability of IGN002. Started May 2016; status: terminated.
02
Drugs
eramkafusp alfa
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02519270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02519270.